论文部分内容阅读
目的观察神经节苷脂联合依达拉奉治疗急性脑梗死的疗效及对炎症因子的影响。方法 2009年8月～2011年8月,156例急性脑梗死患者随机分为两组,观察组78例给予神经节苷脂联合依达拉奉治疗,对照组78例给予血栓通治疗,对比观察两组的临床疗效以及TNF-α、IL-6和CRP水平的变化。结果观察组的总有效率为88.5%,明显高于对照组的69.2%(P﹤0.05)。与治疗前比较,两组治疗后TNF-α、IL-6和CRP水平明显降低,差异均有统计学意义(P﹤0.05)。观察组治疗后TNF-α、IL-6和CRP水平明显低于同期对照组,两组比较差异有统计学意义(P﹤0.05)。结论神经节苷脂联合依达拉奉对急性脑梗死患者进行治疗,能够明显提高临床疗效,降低TNF-α、IL-6和CRP水平,值得临床推广应用。
Objective To observe the curative effect of ganglioside combined with edaravone on acute cerebral infarction and its effect on inflammatory factors. Methods From August 2009 to August 2011, 156 patients with acute cerebral infarction were randomly divided into two groups. 78 patients in the observation group were treated with ganglioside combined with edaravone, while 78 patients in the control group were treated with Xueshuantong. The clinical efficacy and the changes of TNF-α, IL-6 and CRP in both groups were compared. Results The total effective rate of the observation group was 88.5%, which was significantly higher than that of the control group (69.2%, P <0.05). Compared with those before treatment, the levels of TNF-α, IL-6 and CRP in the two groups were significantly decreased after treatment, with statistical significance (P <0.05). After treatment, the levels of TNF-α, IL-6 and CRP in the observation group were significantly lower than those in the control group. The difference between the two groups was statistically significant (P <0.05). Conclusion Ganglioside combined with edaravone in the treatment of patients with acute cerebral infarction can significantly improve the clinical efficacy and reduce the levels of TNF-α, IL-6 and CRP, worthy of clinical application.